|
| deCODE genetics, Inc., a biopharmaceutical company, engages in the research and development of human genetics for common diseases. Its products include DG031, a phase II clinical trial completed product, which would be used for the prevention of heart attack; and DG041, a phase I clinical trial product, for atherosclerosis. The company also has target discovery programs and drug development pipeline products primarily in the areas of inflammatory, central nervous system, cancer, eye, reproductive, and metabolic. deCODE genetics has research collaboration and cross-license agreement with F. Hoffmann-La Roche for the codevelopment of inhibitors of PDE4, as well as an alliance with Merck & Co, Inc. for developing treatments for obesity. The company was co-founded by Kari Stefansson and Jeffrey Gulcher in 1996. deCODE genetics is headquartered in Reykjavik, Iceland. |
- Premarket, intraday, nightly, and weekend updates, which include stock picks with full instructions, market direction (short, intermediate, long term), precious metal, commodity, and currency analysis.
- Provide you stock picks (breakouts) and market direction to help you become
more profitable.
- Voice over chart updates sent to you by e-mail. These updates contain stock picks and market status for a number of different portfolios, which Trending123 is recommending and following.
- Instantaneous e-mail alerts during the trading day when targets have been hit or the status of a position or the market warrants a move. Stock Recommendations for swing traders, day traders, and long term investors.
- Receive instant emails to your computer, organizer, cell phone of breakouts on stocks.....Learn More
|
|
|